Targeting RNA Using Small Molecules For Therapeutic Development
Ashley Smith, Dr. Amanda E. Hargrove
- Abstract
- Currently, the process of creating a new drug with a specific disease target is limited since most therapies target proteins. 70-90% of the human genome is translated into RNA and a small percentage of that is left to be transcribed into proteins. The purpose of this research was to see if the small molecules that have been identified in research to target RNAs translate to what is commercially available. 20 cheminformatic properties that describe small molecule libraries were separated into categories based on similarities and differences using Principal Component Analysis (PCA). In my research, I focused on exploring how these properties fit into four RNA-biased commercial libraries: Life Chemicals, Asinex, Otava, and Reaxense. These four commercial libraries were compared with the R-BIND (RNA-targeted BIoactive ligaNd Database) library. For Life Chemicals, Molecular Weight (MW) was the property that contributed the most to the Principal Components while for Asinex, Otava, and Reaxense, Rings was the property that contributed the most to the Principal Components. These analyses showed the properties that contribute the most variance to the Principal Components, however, my hypotheses were inconclusive. PCA must be run on R-BIND and each commercial library individually in order to get a more precise comparison.
- Presented by
- Ashley Smith
- Institution
- Duke University, Department of Chemistry













